Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Evaluation of sexual function in women at two stages of multiple sclerosis.
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis.
Materials for stem cell factories of the future.
Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model.
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.
Ampyra (dalfampridine) medication guide
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
[Optical coherence tomography in multiple sclerosis].

Pages